Five analysts set USD 14.75 target for Orthofix Medical stock

Published on 10/15/2026 at 21:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due November 3, 2026. Orthofix Medical stock costs EUR 8.55 on October 15, 2026 at 9:05 p.m. CEST, with Nasdaq at USD 9.55.

Analyst view and market context

MarketBeat reported a USD 14.75 consensus target from five analysts on October 11, 2026.
Orthofix Medical is expected to report third-quarter results on November 3, 2026, with consensus revenue of USD 210.69 million.
Orthofix Medical stock costs EUR 8.55 at Lang & Schwarz on October 15, 2026 at 9:05 p.m. CEST, while Nasdaq is at USD 9.55.
Orthofix Medical had a market capitalization of USD 386.2 million as of October 15, 2026.

OFIX, US68752M1080, Illustration mit AI erstellt.

Five analysts backed a USD 14.75 consensus target for Orthofix Medical stock in a report dated October 11, 2026, according to MarketBeat. The target stands 54.45 percent above the Nasdaq quote of USD 9.55. At Lang & Schwarz, OFIX was trading at EUR 8.55 on October 15, 2026 at 9:05 p.m. CEST.

Results date comes into view

MarketBeat estimates that Orthofix Medical will report third-quarter 2026 results on November 3, 2026, before the market opens. The same page lists consensus revenue of USD 210.69 million and consensus earnings of USD 0.11 per share for that quarter.

Revenue beat meets a wider loss

Orthofix reported second-quarter 2026 revenue of USD 210.93 million and an adjusted loss of USD 0.39 per share, according to the company's investor-relations materials at Orthofix Medical. MarketBeat said revenue exceeded consensus of USD 209.28 million, while the adjusted loss was narrower than the consensus loss of USD 0.41 per share. The comparison points to improving sales execution, but earnings remain negative.

Stock stays near yearly low

The Nasdaq quote was USD 9.55 at 3:08 p.m. ET on October 15, 2026, up 3.29 percent from the USD 9.25 prior close. The session range was USD 9.42 to USD 9.73, while the 52-week range was USD 8.50 to USD 16.99. The current price is 12.35 percent above the 52-week low and 43.79 percent below the high.

Valuation and peer comparison

Orthofix Medical had a market capitalization of USD 386.2 million and a trailing P/E ratio of minus 6.22 as of October 15, 2026. The company operates in medical devices, with products spanning spine care, biologics, bone growth stimulation and orthopedic reconstruction.

Comparison with peers

OFIX (Nasdaq, USD): plus 3.29 percent, P/E minus 6.22, market capitalization USD 386.2 million

Globus Medical (NYSE, USD): plus 3.37 percent, P/E 20.24, market capitalization USD 10.6 billion

Stryker (NYSE, USD): plus 3.99 percent, P/E 30.37, market capitalization USD 112.3 billion

The euro quote after hours

Orthofix Medical's euro quotation at Lang & Schwarz stood at EUR 8.55 on October 15, 2026 at 9:05 p.m. CEST. The Nasdaq quote was USD 9.55 at 3:08 p.m. ET on the same date, placing the two venue-specific prices in separate currency perspectives.

The further course of trading is shown by the continuously updated real-time quote of Orthofix Medical stock.